Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cryo-Cell International's Sloan Ratio %
For the Medical Care Facilities subindustry, Cryo-Cell International's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International's Sloan Ratio % Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's Sloan Ratio % falls into.
Cryo-Cell International Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Cryo-Cell International's Sloan Ratio for the fiscal year that ended in Nov. 2023 is calculated as
Cryo-Cell International's Net Income for the trailing twelve months (TTM) ended in Feb. 2024 was 0.221 (May. 2023 ) + 0.681 (Aug. 2023 ) + -11.19 (Nov. 2023 ) + 0.556 (Feb. 2024 ) = $-9.73 Mil.
Cryo-Cell International's Cash Flow from Operations for the trailing twelve months (TTM) ended in Feb. 2024 was 1.989 (May. 2023 ) + 1.942 (Aug. 2023 ) + 3.344 (Nov. 2023 ) + -0.357 (Feb. 2024 ) = $6.92 Mil.
Cryo-Cell International's Cash Flow from Investing for the trailing twelve months (TTM) ended in Feb. 2024 was -1.575 (May. 2023 ) + -3.386 (Aug. 2023 ) + -1.982 (Nov. 2023 ) + -0.341 (Feb. 2024 ) = $-7.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International (AMEX:CCEL) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Feb. 2024, Cryo-Cell International has a Sloan Ratio of -15.18%, indicating there is a warning stage of accrual build up.
Cryo-Cell International Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Cryo-Cell International's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cryo-Cell International (Cryo-Cell International) Business Description
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of Prepacyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. All the business activity of the group functions through the United States and it derives revenue from processing and testing fees and storage fees charged each year for storage and through sales of the Prepacyte CB units.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CCEL has been successfully added to your 